You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    Prostate cancer (PC) is the second leading cause of cancer-related death among American men, and the vast majority of these deaths are due to metastatic, castration-resistant PC (mCRPC). Androgen suppression therapy (AST) is used to treat PC patients, which comprise of: (1) androgen deprivation therapy (ADT) with LHRH agonists or antagonists; (2) blocking CYP17-mediated androgen synthesis with abi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Commercialization Readiness for Nerve Tape: a nerve repair coaptation aid

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: NINDS

    Project Summary This SBIR Commercialization Readiness Pilot project will prepare and achieve the commercial launch of Bio- Circuit Technologies’ Nerve Tape® device for sutureless nerve repair. Nerve injuries are common and result in paralysis, sensory loss, and chronic pain. In current repair techniques, the ends of a cut nerve are microsutured back together under high magnification by a specia ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine

    SBC: ORLANCE, INC            Topic: NIAID

    PROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and mucosal immune responses that can prevent transmission and minimize disease from currently circulatin ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing

    SBC: TWINSTRAND BIOSCIENCES INC            Topic: NCI

    Problem: With a 5-year survival of ~30%, AML is the 6th deadliest cancer, and rt20,000 new patients are diagnosed each year in the United States. Although most patients achieve Complete Remission (CR) with aggressive therapy, most will eventually relapse. The criteria for CR, however, is based on historical diagnostic methods, and patients in CR may carry up to 1010 residual leukemia blasts. Signi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Spinal Reflex Conditioning System for Enhancing Motor Function Recovery After Incomplete Spinal Cord Injury

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: 999

    Project Summary Spinal Cord Injury (SCI) affects ~300,000 people in the US, with 11,000 new cases/year. After SCI, spinal reflex function becomes abnormal, contributing to motor impairments and spasticity that affects 65-78% of people with SCI. Thus, restoring the function of spinal reflex pathways is a major therapeutic goal. Current therapies are only moderately successful; motor function often ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist

    SBC: VIRTUALLY BETTER INC            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Polymeric matrix loaded with tick repellent or toxic compositions for incorporation into fabrics or for granular dispersal

    SBC: BANFIELDBIO INC            Topic: NIAID

    Project Summary/Abstract Within the US, ticks transmit 18 human pathogens, one of the most serious being Lyme disease, with an estimated 476,000 cases per year. Current tick management and human repellent and toxic products were designed either with protection against ticks as an “after-thought” or through the use of a pyrethroid insecticide to which ticks are increasingly developing resistanc ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment

    SBC: SPECTREE INC.            Topic: R

    Project SummaryWe propose developing and validating a novel platform technology that combines the collection and chemical analysis of ultrafine particles using an in-situ multispectral technique. The sample, collected directly onto the analysis substrate, is analyzed via excitation-emission matrix (EEM) spectroscopy. This approach will be validated against laboratory combustion-generated aerosols, ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A new approach to monitoring glycosylation during glycoprotein production

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    PROJECT SUMMARY During the production of therapeutic biologicals, glycosylation has been identified as a critical quality attribute (CQA) that must be carefully monitored to ensure that the desired protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, and serum half-life are consistently obtained. Many factors can affect the composition of the glycan ch ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government